StockNews.com Upgrades USANA Health Sciences (NYSE:USNA) to “Strong-Buy”

USANA Health Sciences (NYSE:USNA) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Thursday.

Separately, DA Davidson decreased their price target on USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating on the stock in a report on Wednesday, October 23rd.

USANA Health Sciences Price Performance

Shares of NYSE:USNA traded up $0.09 during mid-day trading on Thursday, reaching $34.71. 105,555 shares of the company traded hands, compared to its average volume of 81,861. The company’s 50 day moving average price is $37.98 and its 200-day moving average price is $40.51. The firm has a market cap of $661.57 million, a PE ratio of 12.27, a PEG ratio of 1.25 and a beta of 0.89. USANA Health Sciences has a 52 week low of $34.15 and a 52 week high of $54.81.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.07. The business had revenue of $200.22 million during the quarter, compared to analyst estimates of $208.45 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. During the same period in the prior year, the business posted $0.59 earnings per share. On average, research analysts predict that USANA Health Sciences will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Gilbert A. Fuller sold 675 shares of the firm’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $37.71, for a total transaction of $25,454.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.33% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On USANA Health Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC increased its holdings in shares of USANA Health Sciences by 4.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 7,709 shares of the company’s stock worth $292,000 after buying an additional 322 shares during the last quarter. Martingale Asset Management L P lifted its holdings in USANA Health Sciences by 2.1% during the 3rd quarter. Martingale Asset Management L P now owns 16,732 shares of the company’s stock valued at $634,000 after buying an additional 340 shares in the last quarter. KBC Group NV boosted its position in USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after buying an additional 519 shares during the period. Safe Harbor Fiduciary LLC purchased a new position in shares of USANA Health Sciences during the third quarter worth approximately $30,000. Finally, Public Sector Pension Investment Board boosted its holdings in shares of USANA Health Sciences by 5.4% in the second quarter. Public Sector Pension Investment Board now owns 24,270 shares of the company’s stock valued at $1,098,000 after purchasing an additional 1,242 shares during the period. 54.25% of the stock is owned by institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.